Cellistic participates in this year’s ISSCR PSC-Derived Symposium, a gathering for innovators working to advance pluripotent stem cell technologies toward clinical impact. The meeting provides an opportunity to share how Cellistic's platforms are helping developers overcome two persistent challenges in the allogeneic cell therapy space:
(1) generating clinically compliant iPSC starting materials, and
(2) establishing scalable, reproducible manufacturing processes.
Poster 1
Accelerating Allogeneic Cell Therapies Through Clinically Compliant iPSC Line Generation
We showcase how Pulse™ enables early, GMP-aligned iPSC line development using donor-derived starting material, non-integrative reprogramming, and STAR-CRISPR™ editing to generate HLA class I/II–null Allo Chassis™ iPSC lines. This approach minimizes downstream rework and accelerates allogeneic program timelines.
Download the full poster
Poster 2:
Next-Generation Manufacturing for Allogeneic Cell Therapies: The Echo™-NK iPSC Platform Advantage
We present our feeder-free, bioreactor-based Echo™-NK platform, demonstrating high-yield (>1B NK cells/L), reproducible, and GMP-ready manufacturing. While this case focuses on NK cells, the same automated, closed, and standardized principles support other iPSC-derived cell types as well.
